OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
OutSmart Cancer is the podcast for people who refuse to settle for one-size-fits-all cancer care. Hosted by Dr. Dino Prato, founder of Envita Medical Centers, this show offers expert insight into the world of precision oncology, integrative treatments, and the hidden factors that make cancer so hard to treat — and what to do about them.
Dr. Prato and his team have helped thousands of patients that have failed the largest hospitals utilizing the techniques and technology discussed in this series. Whether you’ve been newly diagnosed, are navigating treatment resistance, or want a second opinion grounded in science and compassion, you’ll hear empowering discussions on: DNA, RNA, and immune-based targeting, the truth behind standard protocols, what most doctors miss in treatment planning, stories of hope from patients who’ve been told “there’s nothing more we can do”
We believe in personalized, data-driven medicine — not protocol-based guessing.
You don’t have to fight cancer blindly. You can OutSmart it.
Disclaimer: This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making medical decisions. Results vary and no specific outcomes are guaranteed. Some treatments may not be FDA-approved or available in all locations. Testimonials reflect individual experiences and may not represent typical outcomes. Certain therapies may be offered only at Envita’s international clinic in Hermosillo, Mexico.
OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
Patients Don’t Die of Cancer — They Die of Waiting
Patients don’t die of cancer alone — they die from waiting.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, exposes how the cancer system’s slow approvals, outdated guidelines, and insurance roadblocks cost patients precious time. Care delayed is care denied — and that’s why Dr. Prato and his team built a precision ecosystem to help patients access advanced, individualized care now.
Discover how N of one precision oncology eliminates delays by combining next-generation DNA/RNA sequencing, immune profiling, spatial biology, and molecular heat mapping to design treatments unique to every patient.
🎯 What You’ll Learn in This Episode:
- Why prior authorizations and step therapies delay lifesaving care
- How “population health” oncology ignores your personal biology
- The truth about drug pipelines designed to manage — not cure — cancer
- How precision mapping (DNA, RNA, immune, spatial) speeds effective treatment
- Why waiting on outdated clinical trial models costs lives
How patients see 35x better responses and 43x better quality of life using targeted, personalized care*
📊 In Envita’s published data, late-stage cancer patients achieved dramatically improved outcomes through precision-matched treatments — without the long delays of traditional oncology.*
*(See Outcomes Disclaimer Below)
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576
“Care delayed is care denied. Precision care saves time — and lives.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493